Norcantharidin nanostructured lipid carrier (nctd-nlc) suppresses the viability of human hepatocellular carcinoma hepg2 cells and accelerates the apoptosis

HIGHLIGHTS

  • who: Zijun Yan et al. from the School of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Yunnan, Kunming, China have published the Article: Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the Apoptosis, in the Journal: Journal of Immunology Research of 20/04/2022
  • what: The authors exploited the experiments to explore the effect of NCTD-NLC on liver cancer cells: the HepG2 cells cultured in vitro were given with NCTD-NLC administration; then the estimation on cellular proliferation . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?